Trials / Active Not Recruiting

Active Not RecruitingNCT04205409

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

Nivolumab for Relapsed or Refractory Disease Post Chimeric Antigen Receptor T-Cell Treatment in Patients With Hematologic Malignancies

Status: Active Not Recruiting
Phase: Phase 2
Study type: Interventional
Enrollment: 20 (actual)

Sponsor: University of Washington · Academic / Other
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

This phase II trial studies how well nivolumab works for the treatment of hematological malignancies that have come back (relapsed), does not respond (refractory), or is detectable after CAR T cell therapy. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Detailed description

OUTLINE: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 30 days and then for up to 5 years.

Conditions

Interventions

Type	Name	Description
BIOLOGICAL	Nivolumab	Given IV

Timeline

Start date: 2020-06-05
Primary completion: 2024-09-20
Completion: 2029-08-01
First posted: 2019-12-19
Last updated: 2025-11-03
Results posted: 2025-11-03

Locations

1 site across 1 country: United States

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT04205409. Inclusion in this directory is not an endorsement.